Lisinopril and Cannabis Interaction Profile: What Patients and Prescribers Need to Know

Lisinopril is an ACE (angiotensin-converting enzyme) inhibitor approved by the FDA for hypertension, heart failure, and for improving survival after acute myocardial infarction. It is sold under brand names including Prinivil and Zestril and is also available as a generic tablet. Cannabis refers here to products containing THC (delta-9-tetrahydrocannabinol), CBD (cannabidiol), or both, whether smoked, vaporized, or taken orally.

The direct answer

Cannabis and lisinopril are not known to interact through liver enzyme metabolism in a way that has been clearly demonstrated in humans, because lisinopril is eliminated largely unchanged by the kidneys rather than broken down by cytochrome P450 enzymes. The more concrete concern is pharmacodynamic: THC's vasodilating phase and lisinopril's blood-pressure-lowering action point in the same direction, and stacking two vasodilating exposures is a recognized mechanism for orthostatic hypotension in cardiology generally. This has not been tested as a specific pairing in a controlled trial, so the risk described here is a reasoned extrapolation from how each substance behaves on its own, not a confirmed interaction rate.

Should you avoid cannabis entirely on lisinopril?

Not necessarily, but the decision should depend on your specific risk profile rather than a blanket rule. The useful question is not "does cannabis interact with lisinopril" but "does your combination of age, dose, comorbidities, and cannabis route put you in the group where added blood pressure swings could cause a fall or fainting episode." A healthy 40-year-old on a stable low dose of lisinopril who occasionally uses a low-THC edible carries a different risk than an 80-year-old on lisinopril plus a diuretic who smokes high-potency cannabis flower.

How cannabis affects blood pressure on its own

THC's cardiovascular effect is not fixed. It depends on dose, route, and whether the person uses cannabis regularly.

Inhaled THC (smoking or vaping) is commonly described in the cannabis pharmacology literature as producing an early, brief rise in heart rate and blood pressure in the first several minutes, followed by a longer vasodilatory phase in which blood pressure can fall, sometimes below baseline. Regular, heavy users appear to develop some tolerance to the heart-rate effect, though the vasodilatory phase is generally reported to persist.

Oral THC (edibles, oils, capsules) has a delayed onset, commonly cited as roughly one to three hours, with effects lasting considerably longer than inhaled forms. That longer duration extends the window during which cannabis-related blood pressure changes could overlap with lisinopril's own effect, since lisinopril is a once-daily drug that remains pharmacologically active across the full dosing interval.

CBD behaves differently from THC. It does not meaningfully activate CB1 receptors and does not produce the same heart-rate increase. Small human studies have reported that oral CBD can modestly lower resting blood pressure and blunt the blood-pressure response to stress. Sample sizes in this literature are typically small, and the specific figures reported vary by study; readers and clinicians should verify any precise number against the primary trial report rather than treating it as settled.

Why the combination is a plausible, not proven, risk

By inhibiting the enzyme that converts angiotensin I to angiotensin II, lisinopril reduces vasoconstriction and decreases aldosterone-mediated sodium retention, thereby lowering blood pressure. Orthostatic hypotension is a known risk with ACE inhibitors, especially when starting treatment, using higher doses, or taking them alongside diuretics.

Adding a substance that also vasodilates, even transiently, is mechanistically additive. This is standard cardiovascular reasoning applied to a new pairing, not a result drawn from a trial that enrolled lisinopril patients and gave them cannabis under controlled conditions. No such trial appears to exist in the literature currently available. The absence of a trial is not evidence of safety; it means the risk has to be reasoned from mechanism and from what happens with other combinations of antihypertensive drugs and vasodilating substances, including alcohol.

Reflex tachycardia is part of the same picture. When blood pressure drops quickly, the body compensates with a faster heart rate. Lisinopril does not blunt this reflex, and THC's own early stimulant phase could add to it. For a patient with coronary artery disease, a common reason for being on lisinopril after a heart attack, an unplanned rise in heart rate demand at a moment of lower blood pressure is a more meaningful concern than it would be for a healthy person.

Cannabis and alcohol together are well documented to produce a larger blood pressure drop than either alone. Layering cannabis, alcohol, and lisinopril in the same window is a reasonable scenario to avoid, even without a study of that exact three-way combination.

Who carries more risk

• Adults over 65, who have less cardiovascular reserve to compensate for sudden blood pressure drops
• Patients also taking diuretics, alpha-blockers, or other blood-pressure-lowering drugs alongside lisinopril
• Patients who are dehydrated or volume-depleted from illness, heat, or poor fluid intake
• Patients using high-potency THC products, since contemporary dispensary flower can carry much higher THC concentrations than products studied decades ago
• Patients with heart failure or a recent myocardial infarction, groups for whom lisinopril is specifically indicated and who have less tolerance for hemodynamic swings
• Anyone combining cannabis with alcohol on the same day as their lisinopril dose

What is established, what is plausible, and what remains unverified

Evidence-status assessment: lisinopril and cannabis

The core interaction, stated plainly

Lisinopril and cannabis have no confirmed pharmacokinetic interaction, because lisinopril is cleared mainly by the kidneys rather than by liver enzymes that cannabinoids are known to affect. The clinically relevant concern is pharmacodynamic: THC's vasodilatory phase and CBD's modest blood-pressure-lowering effect both point in the same direction as lisinopril's intended action, which makes orthostatic hypotension, dizziness on standing, and fainting a mechanistically reasonable risk, particularly in older adults, those on additional blood-pressure medications, and those using high-potency or oral cannabis products. This risk has not been measured in a dedicated clinical trial of lisinopril users, so it should be treated as a plausible, monitorable risk rather than a quantified one.

Practical monitoring if you use both

If cannabis use will continue alongside lisinopril, a home blood pressure monitor is useful for catching problems early rather than after a fall or fainting episode.

• Check seated blood pressure before using cannabis, and again roughly one hour afterward, seated and then standing.
• Watch for a systolic drop of 20 mmHg or more, or a diastolic drop of 10 mmHg or more, within a few minutes of standing. That drop defines orthostatic hypotension and is a reason to sit back down and, if it recurs, to contact your prescriber.
• Avoid combining cannabis with alcohol on days you are also taking lisinopril.
• Be cautious with high-THC flower or concentrates until you know how you personally respond; start with the lowest effective amount if cannabis use is going to continue.
• Do not assume timing your lisinopril dose away from cannabis use eliminates the risk. Lisinopril remains active through its full dosing interval, so there is no safe window to exploit.

What to do if you feel faint

Sit or lie down immediately and raise your legs to reduce fall risk. If a blood pressure monitor is available, check your reading. Call emergency services if systolic blood pressure is very low, if you cannot stand without symptoms, or if lightheadedness, chest pain, or a pounding or irregular heartbeat does not resolve within about fifteen minutes. Do not drive while symptomatic.

Special situations worth flagging to your prescriber

Patients on lisinopril for heart failure or after a myocardial infarction have less cardiovascular reserve, so an unplanned drop in blood pressure or spike in heart rate carries more weight than it would in someone taking lisinopril for uncomplicated hypertension alone. Patients with diabetes and hypertension, for whom ACE inhibitors are commonly preferred, should also mention cannabis use, since unexplained blood pressure variability can otherwise be misread as a reason to change the lisinopril dose when cannabis timing may be the actual driver.

Other lisinopril interactions worth knowing

Lisinopril has better-documented interactions outside of cannabis. NSAIDs (such as ibuprofen or naproxen) can blunt its blood-pressure-lowering effect and add kidney strain. Potassium supplements and potassium-sparing diuretics such as spironolactone raise the risk of hyperkalemia. Aliskiren should generally not be combined with lisinopril in patients with diabetes or kidney impairment, per FDA labeling. Share your complete medication and supplement list, including cannabis, with your prescriber or pharmacist.

Talking to your prescriber about cannabis use

Surveys of cannabis-using patients in some clinical populations have reported that a substantial share do not disclose their use to prescribers. Whatever the exact figure in any given population, the practical consequence for lisinopril is real: unexplained blood pressure swings on an otherwise stable dose can be cannabis-related rather than a sign the dose needs adjusting, and a clinician who does not know about cannabis use cannot factor it into that judgment. Most clinicians ask about substance use as routine practice and are not trying to penalize disclosure.

Where the evidence stops

What is established: lisinopril is renally cleared with limited hepatic metabolism, ACE inhibitors carry a class-level orthostatic hypotension risk, and THC produces a biphasic hemodynamic pattern that includes a vasodilatory phase. What is plausible but unproven: that combining cannabis with lisinopril meaningfully raises orthostatic hypotension risk in a way that could be quantified, and that CBD's enzyme-inhibiting effects have any clinically noticeable impact on lisinopril levels. What is not established: any specific numeric risk figure for this particular drug-substance combination, because no dedicated trial or large cohort study of lisinopril users co-using cannabis was identified in the course of preparing this article. Major hypertension and heart failure guidelines from U.S. cardiology and heart failure societies do not currently address cannabis co-use, so clinical judgment based on mechanism, not a guideline recommendation, is what is available today.

This article does not provide individualized dosing or treatment advice. Anyone with questions about their own lisinopril regimen and cannabis use should raise it directly with their prescribing clinician or pharmacist, who can weigh their specific age, comorbidities, other medications, and blood pressure history.